Human papillomavirus infection is associated with the development of malignant and benign neoplasms. Approximately 40 viral types can infect the anogenital mucosa and are categorized into high- and low-risk oncogenic human papillomavirus, depending on their association with the development of cervical carcinoma. High-risk human papillomavirus 16 and 18 are detected in 55% and 15% of all invasive cervical squamous cell carcinomas worldwide, respectively. Low-risk human papillomavirus 6 and 11 are responsible for 90% of genital warts and are also associated with the development of recurrent respiratory papillomatosis. Human papillomavirus preferentially infects mitotic active cells of the basal layer from both mucosal and cutaneous epithelium through microabrasions. The viral life cycle synchronizes with the epithelial differentiation program, which may be due, in part, to the binding of differentially expressed cellular transcription factors to the long control region throughout the various epithelial layers. This review aimed to summarize the current knowledge regarding the mechanisms by which viral gene expression is regulated and the influence of human papillomavirus heterogeneity upon this phenomenon. A better understanding of the regulatory mechanisms may elucidate the particularities of human papillomavirus-associated pathogenesis and may provide new tools for antiviral therapy.

KEYWORDS: Human papillomavirus (HPV); Transcription; Long Control Region; Differentiation.
program is due to, at least in part, the binding of a repertoire of differentially expressed cellular transcription factors (TFs) to the LCR throughout the various layers of the epithelium.

This review summarizes the current knowledge regarding the mechanisms of viral gene expression regulation at the transcription level and the influence of HPV heterogeneity upon this phenomenon. Advances in the knowledge of the regulatory networks may shed light on the particularities of HPV-associated pathogenesis that are relevant for disease establishment and may provide new tools for antiviral therapy.

**The long control region**

The LCR is a noncoding region between the L1 and E6 genes that comprises approximately 10% of the viral genome and is physically divided into three distinct segments: the 5′ segment, the central segment and the 3′ segment.

Most mucosal HPVs present four E2 binding sites (E2bs) distributed along all the three LCR regions. The 5′ segment contains the first E2bs, in addition to the transcription termination and polyadenylation sites for late transcripts. The central segment of the LCR is flanked by two E2bs and has been shown to function as an epithelial-specific transcriptional enhancer (22-24). This segment encloses several motifs that are important either to stimulate or to suppress viral transcriptional activity. These motifs include binding sites to AP1, NF1, TEF1, OCT1, YY1, BRN-3a, NF-IL6, KRF-1, NF-kB, FOXA1, and GATA3, among several others (25-28). Thus, the activation/repression of HPV early promoters involves synergism between these proteins, which vary in affinity for the different cis-elements within the LCR of the different HPV types and variants. Finally, the 3′ segment of the LCR contains two E2bs in addition to an E1 binding site (E1bs) overlapping the origin of replication.

P97 and P105 are the main early promoters of HPVs 16 and 18, respectively, and are also the most well studied. For both high-risk HPVs, transcripts initiated in E6 are differentially edited, codifying all early genes (29) (Figure 1). Additionally, for both viral types a part of the E6 mRNA is spliced out for efficient translation of E7 (30).

In contrast, in low-risk HPVs 6 and 11, two early promoters have been identified, P90 and P270, that enable the individual regulation of E6 and E7 genes, respectively, although the regulation of both promoters is controlled by cis-elements within the LCR (30-35). It is noteworthy the
Transcriptional regulation of HPVs

Transcription is the first step of gene expression control, followed by regulation of mRNA processing and other post-transcriptional events. Transcriptional regulation not only restricts the expression of early and late genes to when they are needed but also limits the range of cell types that HPVs are able to infect, avoids the premature expression of immunogenic viral proteins, and modulates virus biology in response to hormones and growth factors (40-42). HPV transcription is mostly controlled by the E2 viral protein in addition to host cells TFs that bind to specific sequences within the LCR which vary substantially among different viral types and variants (43). HPV gene expression control also involves epigenetic changes, such as nucleosome remodeling and DNA methylation (44).

Approximately 90 bp downstream of the E1 binding site is where the transcription start site is located. A segment of approximately 45 bp within these 90 bp contains a SP1 binding site overlapping the E2bs#3 and a TATA box overlapping E2bs#4. The overlap of both E2bs with these cis-elements occurs in such a way that occupancy by E2 proteins displaces TFIIID and the SP1 factor (45-49). In turn, the binding of SP1 and TFIIID to the LCR sterically inhibits E2 binding, activating early promoters (46,49). In all mucosal HPVs, the spacing of the SP1, TATA, and E2 binding sites at E6/E7 promoters are conserved (28).

E2 is the most important viral transcriptional regulator in HPV early expression and therefore has a high impact on E6 and E7 protein levels (25,50). In preneoplastic and malignant neoplastic lesions, the viral DNA often integrates into the cell genome (51), and integration seems to occur mostly at random (52). However, viral integration usually results in interruption of the E2 gene, abolishing E2-negative transcriptional regulation and resulting in constitutive expression of E6 and E7 proteins (25).

In addition to binding directly to its specific sequence, E2 also influences viral transcription by recruiting cellular factors to the viral genome. One of the best-characterized host interactors of E2 is the bromodomain-containing protein 4 (BRD4), a transcription cofactor and chromatin regulator (53). Both E2-mediated activation and repression of the early promoter require interaction with BRD4 (54,55). A recent study revealed that a phosphorylated region of BRD4 interacts selectively with high-risk E2 proteins. The study showed that the blockage of phospho-BRD4 activity alleviates E2-mediated inhibition of HPV-18 promoter activity (56). Another study demonstrated that BRD4 is capable of directly activating HPV-18 transcription during early stages of infection in an E2-independent manner, indicating that BRD4 plays a central role in the dynamics of viral expression (57).

Another important virally expressed transcriptional regulator is the E8’ E2 protein, which is a product of splicing (58). It was demonstrated that E8’ E2 proteins in HPVs 16, 18, and 31 are potent repressors of viral transcription, and the conserved E8 component of E8’ E2 is capable of recruiting cellular corepressors to inhibit transcription of the viral major early promoter in such a way that is more efficient than the recruitment by the E2 component (59-61). Host cell NCoR/SMRT complexes have been reported to act as corepressors of E8’ E2 proteins in HPVs 1, 8, 16 and 31 (62). This complex encloses G5PS2, HDAC3, NCoR, SMRT and TB1I and TBLR1 proteins and is typically involved in transcriptional repression of cellular genes.

Concerning cellular TFs that bind directly to the LCR, there is a large list of well-characterized regulators (including YY1, AP1, NF1, OCT1, SP1, and CDP), many of which conservatively bind to the central segment of the LCR of several HPV types that infect the mucosa. These regulators have been demonstrated to be relevant not only to HPV epitheliotropism but also to host cell differentiation-dependent regulation of viral infection (25). It was recently reported that the cellular CCCTC-binding factor (CTCF) has a conserved binding site within the E2 open reading frame of high-risk HPVs, in addition to a cluster of cis-elements in the late gene region of the genomes of HPVs 16, 18, 31, 11, and 6. CTCF is recruited during epithelial differentiation to regulate both the transcription of E6 and E7 and transcript processing (63).

García-Vallvé and col. (2006) performed an in silico analysis to search for putative cis-elements within the LCR of 61 papillomavirus (PVs) types infecting 20 different hosts (43). Overall this study indicated that the number and nature of TF binding sites within the LCR can be much broader than described to date, some of which are predicted to be present in most PVs, whereas others cis-elements seems to be restricted to specific PVs. Curiously, in this study, YY1 putative binding sites in the LCR of HPVs 18 and 6 were not found, although the impact of this TF upon the transcriptional activity of both viral types was already demonstrated (64,65). It is noteworthy, however, that the identification of a putative cis-element alone does not implicate that this nucleotide sequence will always be bound by its cognate TF. For instance, many cis-elements within its viral nature may be adjacent or even overlapped with others. We must also take into consideration the existence of degenerate and/or low affinity sites that could increase the number of probable binding sites for a given protein. Furthermore, some TF binding sites are very similar, such as the recognition sequences for TEF-1, TEF-2 and YY1, and these sites may be differently occupied depending upon the availability of each of these proteins (28).

Additionally, the HPV LCR embraces hormone-responsive elements, including glucocorticoid response element (GREs) and progesterone responsive elements (PREs). Complexes formed by steroid hormones and receptor proteins interact with these specific regulatory sequences and either upregulate or downregulate the transcription of viral early genes (66,67). The administration of exogenous estrogen induces HPV-18 LCR activity in both squamous and glandular cells of the cervix and vagina, leading to an increased E6/E7 expression and to a higher susceptibility of neoplastic transformation (68). Likewise, a study regarding smoking-related effects upon the LCR activity revealed that tobacco smoke was able to activate the HPV-16 P97 promoter in a dose-dependent manner in tumor lung cells. However, in nontumor lung cells, the same effect
HPV transcription regulation
Ribeiro AL et al.

Impact of HPV nucleotide heterogeneity upon LCR transcriptional activity

HPV taxonomy is based on the variability of the L1 gene sequence, and viral genomes are classified as new types when these have less than 90% of identity with any other type. Additionally, genome heterogeneity of 1.0-10.0% and 0.5%-1.0% define HPV variant lineages and sublineages, respectively (83). HPV DNA variability studies have been used as an important tool for the analysis of viral evolution. Additionally, it has been observed that specific HPV variants are differentially associated with disease outcome. Since HPV variants show approximately 5% of divergence within the LCR, the impact of HPV nucleotide heterogeneity upon transcriptional activity has been analyzed since nucleotide divergence could influence TF affinity for their recognition sites, thus influencing E6/E7 levels and consequently the carcinogenesis induced by these viruses. In fact, we reported that the HPV-18 P105 promoter is 12 times more transcriptionally active than the HPV-16 P97 promoter (84). These results corroborate previous observations showing that although HPV-18 is 10 times more efficient than HPV-16 in the transformation of human keratinocytes, E6/E7 proteins of both viral types immortalizes these cells with similar efficiency when expressed from a heterologous promoter (85).

Since the early 90s it is known that nucleotide alterations within the LCR among variants of HPV-16 overlap cis-elements (86). Next, it was reported that whereas variants from the A1-A3 sublineages have similar transcriptional activity, variants from the D sublineage attain higher activity, which may support augmented E6 and E7 levels and finally confer enhanced oncogenic potential to specific variants (87). These observations are in line with epidemiological data that indicate that HPV-16 variants from the D lineage are associated with an increased risk of HPV persistence and cervical disease development (88-95). Differences in transcriptional activity were attributed to the E6-proximal end of the LCR, even though it was not possible to implicate the observed differences to a single nucleotide alteration (96). It is also important to note that TF recognition sequences could be created or abolished between HPV variants due to nucleotide changes in the LCR. The expression of viral E2 and E1 replicating proteins has also been influenced by the heterogeneity in the LCR sequence inherent of HPV-16 variants, which has affected the viral replication efficiency as well (97).

BRN3, a long-known cellular transcription factor, binds directly to a specific motif of the HPV LCR, strongly depending on the ectopic expression of HPV-16 E6 and E7 oncoproteins (69).

Chromatin remodeling also plays a pivotal role in regulating HPV transcription. The HPV-16 genome contains nucleosomes in specific positions, one at the center of the viral enhancer and another overlapping the replication origin and the E6 promoter (44). Both nucleosomes repress the activity of the early promoter, which is released by the addition of SP1 and AP1 proteins (70). The influence of nucleosomes upon viral early and late transcription events was also reported in HPV-31: nucleosomes at both promoter regions were activated through histone modifications during differentiation (71).

In addition to the remodeling of nucleosomes, DNA methylation also participates in the epigenetic regulation of HPV gene expression. Host cell methyltransferases methylate HPV DNA, and viral DNA methylation profiles have been related to important features of the viral life cycle (72). Among these features, several studies have focused on the analysis of E2bs methylation, and taken together, the data reveal that differential methylation of the different E2bs has an impact on the activation of viral E6 and E7 expression in cervical lesions (73-75). Additionally, analysis of the methylation status of CpG dinucleotides within TF binding sites in the LCR were identified, most of which had not yet been published. Twenty-eight TFs that stimulated and 36 that repressed transcription were activated through histone modifications during differentiation (71).

However, the functional relevance and how these various factors contribute to transcription regulation remains unclear (77,78). Recent findings indicate that transcript elongation is also a critical step for viral late gene upregulation. It was demonstrated that cyclin dependent kinase 9 (CDK9), CDK8 and Brd4 are recruited to activate the HPV-16 late promoter under differentiation conditions and to assist Pol II complex activity until transcription is accomplished (79). The viral oncoprotein E7 might also activate the HPV-16 late promoter, indicating that the virus, per se, also plays an active role in regulating its own expression (80).

The study of HPV regulatory elements progressed rapidly for approximately 15 years, beginning in the early 1980s, but interest declined dramatically, which was possibly associated with limitations of the available methodologies. However, the understanding of HPV transcriptional regulation is far from achieving maturity. In the last decade the development of array technologies made possible the identification of several additional TFs that impact HPV transcriptional activity. Competition assays using an array comprising 345 consensus binding sites for different TFs identified factors that specifically bind to the HPV-16 LCR in differentiated and undifferentiated cells (77). It is noteworthy that the methodology used was able to confirm several TFs already described to influence the expression of HPVs, although most of the associations reported were still unpublished.

In our laboratory a powerful approach was used to analyze the effect of 704 TFs upon the transcriptional activity of HPVs 16 and 18 using a large-scale transfection assay (26). Twenty-eight TFs that stimulated and 36 that repressed the LCR were identified, most of which had not yet been described. Although many of the TFs appear to act by indirect mechanisms, binding sites on the viral LCR for a subset of these modulators were identified. Among these, FOXA1 had the greatest effect upon HPV-16 and HPV-18 transcriptional activities, and this was a direct effect, as we were able to show in vivo binding of FOXA1 to the LCR in both viral types. Moreover, the differential expression patterns of FOXA1 indicate that this protein may be important to HPV-associated carcinogenesis: we observed that FOXA1 is expressed at higher levels in immortalized and HPV-transformed cell lines than it is in normal cells (26), and FOXA1 was further shown to be strongly expressed in basal epithelial cells, preinvasive lesions, and cervical and head and neck carcinomas (81). Sex determining region Y (SRY)-box 2 (SOX2) has also been recently proposed as a transcriptional repressor of the HPV-16 LCR; SOX2 binds to three putative binding sites identified in the enhancer sequence of the LCR through direct interactions and leads to the inhibition of E6 and E7 expression (82).
stimulating its activity (98,99). BRN3 and nicotine from smoking were shown to have a synergistic effect upon the LCR in a variant-specific manner (100). The BRN3/nicotine response increases the transcription HPV-16 E6/E7 genes and was shown to be related to higher grades of cervical intraepithelial neoplasia and cancer.

Although it was observed that the LCR sequence of HPV-18 and 58 is more conserved than the LCR sequence of HPV-16, there are significant differences in the early promoter activity among molecular variants of both viral types (84,101). For instance, we observed that Asian-Amerindian variants achieved higher transcriptional activity than variants from the European branch (84) (Figure 2A).

Genome variability of low-risk HPVs 6 and 11 has also been evaluated, and molecular variants of both viral types were phylogenetic grouped (102-104). It was reported that a variant from the HPV-6 B1 sublineage is ten times more transcriptionally active than a B3 variant is (105) (Figure 2B). Since a significant association between variants of the B1 sublineage and the development of GWs was recently described, it is possible to hypothesize that the increased transcriptional efficiency could impact the increased expression of viral E1 and E2, which can confer B1 variants to have an increased replication potential (106). Moreover, the results support a crucial role of the ELF1 protein in the lower transcriptional activity observed for the B3 variant (105). A correlation between the transcriptional activity of specific HPV-11 variants and the clinical aggressiveness of RRP has also been reported (107).

Additionally, it was reported that duplication in the early viral promoter sequence of HPV-11 was associated with a higher degree of disease severity (108).

A broader comprehension of HPV mRNA expression and its regulation could lead to the development of novel diagnostic approaches and reveal strategic cellular targets for the development of innovative antiviral therapies (25). Even though inhibition of transcriptional regulatory factors could be harmful to normal cells once it is required for host cell homeostasis, these proteins could be inhibited using compounds targeting specific LCR sequences, thus affecting viral life cycle. Therefore, a molecule that could specifically bind to cis-responsive elements indispensable for E6 and E7 transcription of different viral types and variants could interfere with the transformation process that is dependent on the constitutive expression of both oncoproteins.

A recent approach based on TF research relied on the identification of molecular signatures associated with HPV positivity and the prognosis of head and neck cancers outcome. In this context, differential expression of key transcription factors, such as API, activator of transcription 3 (STAT3) and NF-kB, was reported between HPV-positive and HPV-negative cancers (109-111). More specifically, in HPV-positive squamous cell carcinomas of the oral cavity, higher levels of API and NF-kB in addition to a lack of STAT3 was observed, and this pattern was suggested to be useful for discriminating tumors with a better prognosis (110). Therefore, the study of TF expression patterns may also provide useful prognostic biomarkers as well as novel insights to the molecular aspects of HPV-driven carcinogenesis.

**REFERENCES**

1. Van Doorslaer K, Bernard HU, Chen Z, de Villiers EM, zur Hausen H, Burk RD. Papillomaviruses: evolution, Linnaean taxonomy and current nomenclature. Trends Microbiol. 2011;19(2):49-56, http://dx.doi.org/10.1016/j.tim.2010.11.004.

2. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009;10(4):321-2, http://dx.doi.org/10.1016/S1470-2045(09)70096-8.

3. zur Hausen H, Meinhof W, Scheiber W, Borinkamm GW. Attempts to detect virus-specific DNA in human tumors. I. Nucleic acid hybridizations with complementary RNA of human wart virus. Int J Cancer. 1974;13(5):650-6, http://dx.doi.org/10.1002/ijc.2910130509.

4. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1790-99, http://dx.doi.org/10.1086/657221.

5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9, http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.

6. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-75, http://dx.doi.org/10.1158/1055-9966.EPI-04-0551.

7. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018;47:14-26, http://dx.doi.org/10.1016/j.bpobgyn.2017.08.006.

8. Buchinsky FJ, Donfack J, Derkdaj CS, Choi SS, CConey SF, CMeyer CM 3rd, et al. Age of child, more than HPV type, is associated with clinical
course in recurrent respiratory papillomatosis. PLos One. 2008;3(5): e2263, http://dx.doi.org/10.1371/journal.pone.0002263.

9. Larson DA, Derkay CS. Epidemiology of recurrent respiratory papil- lomatisis. APMIS. 2010;118(6):450-4, http://dx.doi.org/10.1111/j.1600- 0463.2010.01399.x.

10. Okagaki T, Clark BA, Zachow KR, Twiggs LB, Ostrow RS, Pess E, et al. Presence of human papillomavirus in verrucous carcinoma (Ackerman) of the vagina. Immunocytochemical, ultrastructural, and DNA hybridization studies. Arch Pathol Lab Med. 1986;110(7):567-70.

11. Rando RF, Gorf RE, Chirikjian JG, Lancaster WD. Isolation and char- acterization of a novel human papillomavirus type 6 DNA from an invasive squamous carcinoma of the vulva. Virology. 1988;165(1):225-33, http://dx.doi.org/10.1016/0042-6822(88) 90676-9.

12. Alemany L, Cubilla A, Halec G, Kasamatsu E, Quiroz B, Masferrer E, et al. Role of Human Papillomavirus in Penile Carcinomas Worldwide. Eur Urol. 2016;69(5):953-61, http://dx.doi.org/10.1016/j.eururo.2015.12.007.

13. Kitsato H, Denuis H, zur Hausen H, Sorger K, Rösl F, de Villiers EM. Presence of human papillomavirus in verrucous carcinoma (Ackerman) of the vagina. Immunocytochemical, ultrastructural, and DNA hybridization studies. Arch Pathol Lab Med. 1986;110(7):567-70.

14. Bercovich JA, Centeno CR, Aguilar OG, Grinstein S, Kahn T. Presence and integration of human papillomavirus type 6 in a tonsillar carcinoma. J Gen Virol. 1991;72(2 Pt 1):2569-72, http://dx.doi.org/10.1099/0022-1317-72-10-2569.

15. Ott M, Böhm S, Wilczynski SP, Pfister T. Expression of the different viral mRNAs of human papillomavirus 6 in a squamous-cell carcinoma of the bladder and the cervix. Int J Cancer. 1993;53(6):924-31, http://dx.doi.org/10.1002/ijc.2910530610.

16. Wilczynski SP, Ott M, Cook N, Liao SY, Ifter H. Tumor human papillomavirus type 6 in squamous cell carcinoma of the bladder and cervix. Hum Pathol. 1993;24(1):106-20, http://dx.doi.org/10.1016/0196-9735(93)90066-R.

17. Berchowitz JA, Centeno CR, Aguilar OG, Grinstein S, Kahn T. Presence and integration of human papillomavirus type 6 in a tonsillar carcinoma. J Gen Virol. 1991;72(2 Pt 1):2569-72, http://dx.doi.org/10.1099/0022-1317-72-10-2569.

18. Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol. 2005;32(Suppl 1): S1-6, http://dx.doi.org/10.1016/j.jcv.2004.10.021.

19. Van Doeselaar K, McBride AA. Molecular archeological evidence in support of the repeated loss of a papillomavirus gene. Sci Rep. 2016; 6:33020, http://dx.doi.org/10.1038/srep33020.

20. Doorbar J, Egawa N, Griffith H, Kranjec C, Murakami I. Human papillomavirus molecule and biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2-23, http://dx.doi.org/10.1002/rmv.1822.

21. Ozburn MA, Meyers C. Characterization of late gene transcripts expres- sed during vegetative replication of human papillomavirus type 31b. J Virol. 1997;71(7):5161-72.

22. Chin MT, Broker TR, Chow LT. Identification of a novel constitutive promoter of human papillomavirus type 16 E2 by the viral transcription factor E2. J Virol. 1997;71(10):8676-86, http://dx.doi.org/10.1016/S0022-538X(97)40011-X.

23. Cid A, Auewarakul P, Garcia-Carranca A, Ovseiovich R, Gaissert H, et al. Characterization of a novel human papillomavirus type 6 DNA isolated from an invasive squamous carcinoma of the vulva. Virology. 1988;165(1):225-33, http://dx.doi.org/10.1016/0042-6822(88)90676-9.

24. Bernard HU. Regulatory elements in the viral genome. Virology. 2013;445(1-2):197-204, http://dx.doi.org/10.1016/j.virol.2013.04.035.

25. Garcia-Vallve S, Iglezias- Rozas JR, Alonso A, Bravo KC. Different papil- lomaviruses have different repertoires of transcription factor binding sites: convergence and divergence in the upstream regulatory region. BMC Evol Biol. 2006;6:20, http://dx.doi.org/10.1186/1471-2148-6-20.

26. Soto D, Song C, McLaughlin-Drubin ME. Epigenetic Alterations in Human Papillomavirus-Associated Cancers. Viruses. 2017;9(9). pii: E248, http://dx.doi.org/10.3390/v9090248.

27. Bouvard V, Storey A, Pim D, Banks L. Characterization of the human papillomavirus E2 protein: evidence of trans-activation and trans-repression in cervical keratinocytes. EMBO J. 1994;13(22):5451-9.

28. Demeret C, Yaniv M, Thierry F. The E2 transcriptional repressor can compensate for Sp1 activation of the human papillomavirus type 18 early promoter. J Virol. 1994;68(9):5707-82.

29. Dostatni N, Lambert PF, Sousa R, Ham J, Howley PM, Yaniv M. The functional BPV-1 E2 trans-activating protein can act as a repressor by preventing formation of the initiation complex. Genes Dev. 1991;5(9):1445-57, http://dx.doi.org/10.1101/gad.5.9.1445.

30. Gloss B, Bernard HU, Seedorf K, Klock G. The upstream regulatory region of the human papillomavirus virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. EMBO J. 1987;6(12):3735-43.

31. Tan SH, Leong LE, Walker PA, Bernard HU. The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFF1. J Virol. 1994;68(10):6411-20.

32. Bernard HU. Human papillomavirus type 18 and 16 early promoters differ. Hum Pathol. 1996;27(7):512-6.

33. Bernard HU. Role of Human Papillomavirus in Penile Carcinomas Worldwide. Curr Clin Oncol. 2018;73(suppl 1):e486s.
62. Dreer M, Fertey J, van de Poel S, Straub E, Madlung J, Macek B, et al.
61. Dreer M, van de Poel S, Stubenrauch F. Control of viral replication and
60. Stubenrauch F, Zobel T, Iftner T. The E8 domain confers a novel long-
56. Wu SY, Nin DS, Lee AY, Simanski S, Kodadek T, Chiang CM. BRD4
75. Leung TW, Liu SS, Leung RC, Chu MM, Cheung AN, Ngan HY.
72. Fernandez AF, Esteller M. Viral epigenomes in human tumorigenesis.
71. Wooldridge TR, Laimins LA. Regulation of human papillomavirus
70. Stünkel W, Bernard HU. The chromatin structure of the long control
68. Park JS, Rhyu JW, Kim CJ, Kim HS, Lee SY, Kwon YI, et al. Neoplastic
67. Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R. Oestrogen stimulates
65. Bauknecht T, Angel P, Royer HD, zur Hausen H. Identification of a negative
64. Ai W, Narahari J, Roman A. Yin yang 1 negatively regulates the
63. Paris C, Pentland I, Groves I, Roberts DC, Powis SJ, Coleman N, et al.
5205.2000.
516. Tobacco smoke activates human papillomavirus 16 p97 promoter and
515. (02)00106-3.
514. Gynecol Oncol. 2003;89(3):360-8, http://dx.doi.org/10.1016/S0090-8258
513. Molecular variants of human papillomavirus types 16 and 18. Cancer Res.
512. 2010;70(8):3159-69, http://dx.doi.org/10.1158/0008-5472.CAN-09-4179.
511. Human papillomavirus type 16 variants in cervical cancer from an
510. Human papillomavirus type 16 variants in cervical cancer: a case-control study. J Natl Cancer Inst. 2001;93(17):
509. et al. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst. 2001;93(17):1235-30, http://dx.doi.org/10.1093/jnci/93.17.1235.
508. Hildesheim A, Herrero R, Wacholder S, Bratti MC, Sherman ME, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer. 2001;84(9):1219-26, http://dx.doi.org/10.1054/bjoc.2001.1779.
507. Jones-Gill K, Sichero L, Allman D, Olshen AB, Gnepp DR, Ballester V, Villa LL. Human papillomavirus type 16 variants in cervical cancer from an admixed population in Brazil. Med Virol. 2008;80(9):1639-45, http://dx.doi.org/10.1080/10448600802458774.
506. Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res. 2010;70(8):3159-69, http://dx.doi.org/10.1158/0008-5472.CAN-09-4179.
505. Sichero L, Ferreira T, Duarte-Franco E, Ferenczy A, Franco EL, et al. High grade cervical lesions are caused preferentially by non-Euro-american variants of HPV 16 and 18. Int J Cancer. 2007;120(8):1763-8, http://dx.doi.org/10.1002/ijc.22481.
504. Villa LL, Sichero L, Rabah P, Caballero O, Ferenczy A, Rohan T, et al. Molecular variants of human papillomavirus types 16 and 18 and preferentially associated with cervical neoplasia. J Gen Virol. 2000;81(Pt 12):2959-68, http://dx.doi.org/10.1099/0022-1317-81-12-2959.
503. D’Souza RE, Tüller E, Wentzensen N, Mathews C, Allen RA, Shanesmith R, et al. HPV16 variant lineages, clinical stage, and survival in women with invasive cervical cancer. Infect Agent Cancer. 2011;6:19, http://dx.doi.org/10.1186/1748-5996-6-19.
502. Kämmer C, Warthorst U, Torres-Martinez N, Wheeler CM, Pfister H. Sequence analysis of the long control region of human papillomavirus type 16 variants and functional consequences for P79 promoter activity. J Gen Virol. 2000;81(Pt 8):1975-81.
501. Hubert WG. Variant upstream regulatory region sequences differentially regulate human papillomavirus type 16 DNA replication throughout the
500. Viral Transcription upon Human Papillomavirus 18 Infection of Primary Keratinocytes. J Virol. 2000;74(9):4139-49, http://dx.doi.org/10.1128/JVI.74.9.4139-4149.2000.
499. Wacholder S, Bratt K, Anderlini J, Hildesheim A, McLaughlin JK, et al. HPV16 Transcription. Viruses. 2017;9(7).pii:E175, http://dx.doi.org/10.3390/v9070175.
498. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324(1-2):17-27, http://dx.doi.org/10.1016/j.virol.2004.03.033.
497. Hubert WG. Variant upstream regulatory region sequences differentially regulate human papillomavirus type 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst. 2001;93(17):1235-30, http://dx.doi.org/10.1093/jnci/93.17.1235.
496. Hildesheim A, Herrero R, Wacholder S, Bratti MC, Sherman ME, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer. 2001;84(9):1219-26, http://dx.doi.org/10.1054/bjoc.2001.1779.
495. Zuna RE, Tuller E, Wentzensen N, Mathews C, Allen RA, Shanesmith R, et al. HPV16 variant lineages, clinical stage, and survival in women with invasive cervical cancer. Infect Agent Cancer. 2011;6:19, http://dx.doi.org/10.1186/1748-5996-6-19.
494. Kämmer C, Warthorst U, Torres-Martinez N, Wheeler CM, Pfister H. Sequence analysis of the long control region of human papillomavirus type 16 variants and functional consequences for P79 promoter activity. J Gen Virol. 2000;81(Pt 8):1975-81.
493. Hubert WG. Variant upstream regulatory region sequences differentially regulate human papillomavirus type 16 DNA replication throughout the
viral life cycle. J Virol. 2005;79(10):5914-22, http://dx.doi.org/10.1128/JVI.79.10.5914-5922.2005.

98. Lillycrop KA, Budrahan VS, Lakin ND, Terrenghi G, Wood JN, Polak JM, et al. A novel POU family transcription factor is closely related to Brn-3 but has a distinct expression pattern in neuronal cells. Nucleic Acids Res. 1992;20(19):5093-6, http://dx.doi.org/10.1093/nar/20.19.5093.

99. Ndisang D, Budhram-Mahadeo V, Latchman DS. The Brn-3a transcription factor plays a critical role in regulating human papilloma virus gene expression and determining the growth characteristics of cervical cancer cells. J Biol Chem.1999 ;274(40):28521-7, http://dx.doi.org/10.1074/jbc.274.40.28521.

100. Ndisang D, Khan A, Lorenzato F, Sindos M, Singer A, Latchman DS. The cellular transcription factor Brn-3a and the smoking-related substance nicotine interact to regulate the activity of the HPV URR in the cervix. Oncogene. 2010;29(18):2701-11, http://dx.doi.org/10.1038/onc.2010.33.

101. Raiol T, de Amorim RM, Galante P, Martins CR, Villa LI, Sicbero L. HPV-58 molecular variants exhibit different transcriptional activity. Intervirology. 2011;54(3):146-50, http://dx.doi.org/10.1159/000320199.

102. Burk RD, Chen Z, Harari A, Smith BC, Kocjan BJ, Mavero PJ, et al. Classification and nomenclature system for human Alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages. Acta Dermatovenerol Alp Panonica Adriat. 2011;20(3):113-23.

103. Jelen MM, Chen Z, Kocjan BJ, Burt FJ, Chan PK, Choufy D, et al. Global genomic diversity of human papillomavirus 6 based on 724 isolates and 190 complete genome sequences. J Virol. 2014;88(13):7307-16, http://dx.doi.org/10.1128/JVI.00621-14.

104. Jelen MM, Chen Z, Kocjan BJ, Hojnjak L, Burt FJ, Chan PKS, et al. Global Genomic Diversity of Human Papillomavirus Type 11 Based on 433 Isolates and 78 Complete Genome Sequences. J Virol. 2016;90(11):5503-13, http://dx.doi.org/10.1128/JVI.03149-15.

105. Measso do Bonfim C, Simão Sobrinho J, Lacerda Nogueira R, Salgado Kupper D, Cardoso Pereira Valeira F, Lacerda Nogueira M, et al. Differences in Transcriptional Activity of Human Papillomavirus Type 6 Molecular Variants in Recurrent Respiratory Papillomatosis. PLoS One. 2015;10(7):e0132325, http://dx.doi.org/10.1371/journal.pone.0132325.

106. Flores-Díaz E, Sereday KA, Ferreira S, Strak B, Sobrinho JS, Baggio ML, et al. HPV-11 variability, persistence and progression to genital warts in men: the HIM study. J Gen Virol. 2017;98(9):2339-42, http://dx.doi.org/10.1099/gsv.0.000896.

107. Gáll T, Kis A, Tatár TZ, Kardos G, Gergely L, Szarka K. Genomic differences in the background of different severity in juvenile-onset respiratory papillomatosis associated with human papillomavirus type 11. Med Microbiol Immunol. 2013;202(3):353-63, http://dx.doi.org/10.1007/s00430-013-0297-y.

108. Yuan CH, Filipova M, Duerrsen-Hughes P. Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy. Viruses. 2012;4(12):3831-50, http://dx.doi.org/10.3390/v4123831.

109. Gaykalova DA, Manola JB, Ozawa H, Zizkova V, Morton K, Bishop JA, et al. NF-κB and stat3 transcription factor signatures differentiate HPV-positive and HPV-negative head and neck squamous cell carcinoma. Int J Cancer. 2015;137(8):1879-89, http://dx.doi.org/10.1002/ijc.29558.

110. Verma G, Vishnoi K, Tyagi A, Jadi M, Singh T, Goel A, et al. Characterization of key transcription factors as molecular signatures of HPV-positive and HPV-negative oral cancers. Cancer Med. 2017;6(3):591-604, http://dx.doi.org/10.1002/cam4.983.

111. Zhang W, Wu X, Hu L, Ma Y, Xiu Z, Huang B, et al. Overexpression of Human Papillomavirus Type 16 Oncoproteins Enhances Epithelial-Mesenchymal Transition via STAT3 Signaling Pathway in Non-Small Cell Lung Cancer Cells. Oncol Res. 2017;25(5):843-52, http://dx.doi.org/10.3727/096504017X14813880882288.